NASDAQ : MDGL
Madrigal Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 431.7 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 9.97B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 9.94B |
| Enterprise Value | 9.45B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 23.10M |
| Shares Outstanding | 23.10M |
| Shares Change (YoY) | +3.96% |
| Shares Change (QoQ) | -20.53% |
| Owned by Insiders (%) | 5.25% |
| Owned by Institutions (%) | 71.92% |
| Float | 13.72M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.74 |
| Forward PS | 5.57 |
| PB Ratio | 18.98 |
| P/TBV Ratio | 19.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 7.36 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.20 |
| Quick Ratio | 2.76 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.24 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -53.31% |
| Return on Assets (ROA) | -17.84% |
| Return on Invested Capital (ROIC) | -23.84% |
| Return on Capital Employed (ROCE) | -37.06% |
| Weighted Average Cost of Capital (WACC) | -1.24% |
| Revenue Per Employee | $1.40M |
| Profits Per Employee | -$355,295 |
| Employee Count | 915 |
| Asset Turnover | 1.14 |
| Inventory Turnover | 1.34 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -1.05 |
| 52-Week Price Change | +2.08% |
| 50-Day Moving Average | 498.66 |
| 200-Day Moving Average | 499.95 |
| Relative Strength Index (RSI) | 29.50 |
| Average Volume (20 Days) | 301,176 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.19M |
| Short Previous Month | 2.40M |
| Short % of Shares Out | 9.50% |
| Short % of Float | 15.99% |
| Short Ratio (days to cover) | 7.90 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.28B |
| Gross Profit | 1.17B |
| Operating Income | -322.62M |
| Pretax Income | -325.10M |
| Net Income | -325.10M |
| EBITDA | -321.10M |
| EBIT | -322.62M |
| Loss Per Share | -$14.22 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 838.75M |
| Total Debt | 347.75M |
| Net Cash | 491.00M |
| Net Cash Per Share | $21.25 |
| Equity (Book Value) | 523.72M |
| Book Value Per Share | 22.68 |
| Working Capital | 824.98M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -197.72M |
| Capital Expenditures | -8.57M |
| Depreciation & Amortization | 1.52M |
| Net Borrowing | 228.34M |
| Free Cash Flow | -206.29M |
| FCF Per Share | -$8.93 |
Margins
| Measure | Value |
|---|
| Gross Margin | 91.48% |
| Operating Margin | -25.13% |
| Pretax Margin | -25.32% |
| Profit Margin | -25.32% |
| EBITDA Margin | -25.01% |
| EBIT Margin | -25.13% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.96% |
| Shareholder Yield | -3.96% |
| Earnings Yield | -3.30% |
| FCF Yield | -2.07% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $685.22 |
| Price Target Difference | 59.22% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (3Y) | 44.02% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 7.29 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |